{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:12:32Z","timestamp":1779927152823,"version":"3.53.1"},"reference-count":30,"publisher":"Informa Healthcare","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2010,12,1]]},"DOI":"10.1185\/03007995.2010.533648","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T16:33:47Z","timestamp":1289320427000},"page":"2861-2869","source":"Crossref","is-referenced-by-count":48,"title":["Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia"],"prefix":"10.1185","volume":"26","author":[{"given":"Eric Q.","family":"Wu","sequence":"first","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Yu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Bollu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Guo","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2010,11,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.4.1.85"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20006"},{"key":"CIT0003","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. V.2.2010. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp [Last accessed 6 July 2010]"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"CIT0006","unstructured":"Gu\u00e9rin A, Guo A, Williams D, et al. Treatment Patterns of Chronic Myelogenous Leukemia Patients with Sub-Optimal Response to Imatinib. Presented at the 2009 ASCO Annual Meeting, Orlando, Florida, USA, May 29 \u2013 June 2, 2009"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.s.040"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.419"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22661"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.11.001"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1200\/jco.2009.27.15_suppl.7029","volume":"27","author":"Kantarjian HM","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.05.003"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"CIT0019","unstructured":"US Food and Drug Administration. Nilotinib hydrochloride monohydrate. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf (Last accessed 15 July 2010)"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.4065\/84.2.161"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003637282"},{"key":"CIT0023","unstructured":"US Food and Drug Administration: Dasatinib. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021986s004lbl.pdf (Last accessed 15 July 2010)"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"CIT0025","unstructured":"US Department of Health and Human Services: International Classification of Diseases, Ninth Revision, Clinical Modification, ed 4. Washington, US Government Printing Office, 1991"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00543.x"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903396469"},{"key":"CIT0030","doi-asserted-by":"crossref","unstructured":"Santos FP, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 2010 Aug;150(3):303-12","DOI":"10.1111\/j.1365-2141.2010.08245.x"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2010.533648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T08:30:31Z","timestamp":1636792231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2010.533648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,9]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12,1]]}},"alternative-id":["10.1185\/03007995.2010.533648"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2010.533648","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,9]]}}}